PD-217,014 is a drug developed by
Pfizer and related to
gabapentin, which similarly binds to the α2δ
calcium channels (
1 and
2). It was developed as a potentially more potent successor to gabapentin and
pregabalin, along with several other analogues such as
atagabalin and
4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.[1]
References
^Ohashi K, Kawai M, Ninomiya N, Taylor C, Kurebayashi Y (2008). "Effect of a new alpha 2 delta ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats". Pharmacology. 81 (2): 144–50.
doi:
10.1159/000110737.
PMID17989503.
S2CID84708161.
PD-217,014 is a drug developed by
Pfizer and related to
gabapentin, which similarly binds to the α2δ
calcium channels (
1 and
2). It was developed as a potentially more potent successor to gabapentin and
pregabalin, along with several other analogues such as
atagabalin and
4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.[1]
References
^Ohashi K, Kawai M, Ninomiya N, Taylor C, Kurebayashi Y (2008). "Effect of a new alpha 2 delta ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats". Pharmacology. 81 (2): 144–50.
doi:
10.1159/000110737.
PMID17989503.
S2CID84708161.